Roche: breast cancer drug cuts risk of recurrence in study
(CercleFinance.com) - Roche's Kadcyla cuts the risk of the disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer, the Swiss company said on Wednesday, citing the results of a late-stage trial.
The phase III study met its primary endpoint, showing that Kadcyla reduced the risk of disease recurrence or death by 50% compared to Herceptin, another Roche drug, after surgery in people with HER2-positive early breast cancer having residual disease, the drugmaker said.
At three years, 88% of people treated with Kadcyla did not see their breast cancer return, compared to 77% treated with Herceptin, representing an 11-point improvement, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The phase III study met its primary endpoint, showing that Kadcyla reduced the risk of disease recurrence or death by 50% compared to Herceptin, another Roche drug, after surgery in people with HER2-positive early breast cancer having residual disease, the drugmaker said.
At three years, 88% of people treated with Kadcyla did not see their breast cancer return, compared to 77% treated with Herceptin, representing an 11-point improvement, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.